Novo Nordisk considers exploring GLP-1 drugs like semaglutide for addiction treatment, following Eli Lilly's interest.
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results